This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feldmann, G. Articles by Maitra, A. Search for Related Content PubMed PubMed Citation Articles by Feldmann, G. Articles by Maitra, A.

Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers

Departments of ¹ Pathology, ² Surgery, ³ Comparative Medicine, and ⁴ Oncology, ⁵ The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Georg Feldmann, Department of Pathology, Johns Hopkins University School of Medicine, CRB2, Room 316, 1550 Orleans Street, Baltimore, MD 21231. Phone: 410-955-3511; Fax: 410-614-0671; E-mail: gfeldma4{at}jhmi.edu.

In the context of pancreatic cancer, metastasis remains the most critical determinant of resectability, and hence survival. The objective of this study was to determine whether Hedgehog (Hh) signaling plays a role in pancreatic cancer invasion and metastasis because this is likely to have profound clinical implications. In pancreatic cancer cell lines, Hh inhibition with cyclopamine resulted in down-regulation of snail and up-regulation of E-cadherin, consistent with inhibition of epithelial-to-mesenchymal transition, and was mirrored by a striking reduction of in vitro invasive capacity (P < 0.0001). Conversely, Gli1 overexpression in immortalized human pancreatic ductal epithelial cells led to a markedly invasive phenotype (P < 0.0001) and near total down-regulation of E-cadherin. In an orthotopic xenograft model, cyclopamine profoundly inhibited metastatic spread; only one of seven cyclopamine-treated mice developed pulmonary micrometastases versus seven of seven mice with multiple macrometastases in control animals. Combination of gemcitabine and cyclopamine completely abrogated metastases while also significantly reducing the size of "primary" tumors. Gli1 levels were up-regulated in tissue samples of metastatic human pancreatic cancer samples compared with matched primary tumors. Aldehyde dehydrogenase (ALDH) overexpression is characteristic for both hematopoietic progenitors and leukemic stem cells; cyclopamine preferentially reduced "ALDH-high" cells by 3-fold (P = 0.048). We confirm pharmacologic Hh pathway inhibition as a valid therapeutic strategy for pancreatic cancer and show for the first time its particular efficacy against metastatic spread. By targeting specific cellular subpopulations likely involved in tumor initiation at metastatic sites, Hh inhibitors may provide a new paradigm for therapy of disseminated malignancies, particularly when used in combination with conventional antimetabolites that reduce "bulk" tumor size. [Cancer Res 2007;67(5):2187–96]

This article has been cited by other articles:

				P. S. Steeg, R. L. Anderson, M. Bar-Eli, A. F. Chambers, S. A. Eccles, K. Hunter, K. Itoh, Y. Kang, L. M. Matrisian, J. P. Sleeman, et al. Preclinical Drug Development Must Consider the Impact on Metastasis Clin. Cancer Res., July 15, 2009; 15(14): 4529 - 4530. [Full Text] [PDF]

				P. Olson and D. Hanahan Breaching the Cancer Fortress Science, June 12, 2009; 324(5933): 1400 - 1401. [Abstract] [Full Text] [PDF]

				J. Xie Activation of Hedgehog Signaling in Human Cancer: Basic Mechanisms and Clinical Implications Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 25 - 41. [Full Text] [PDF]

				C. A. Iacobuzio-Donahue, B. Fu, S. Yachida, M. Luo, H. Abe, C. M. Henderson, F. Vilardell, Z. Wang, J. W. Keller, P. Banerjee, et al. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer J. Clin. Oncol., April 10, 2009; 27(11): 1806 - 1813. [Abstract] [Full Text] [PDF]

				M. E. Mullendore, J.-B. Koorstra, Y.-M. Li, G. J. Offerhaus, X. Fan, C. M. Henderson, W. Matsui, C. G. Eberhart, A. Maitra, and G. Feldmann Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2291 - 2301. [Abstract] [Full Text] [PDF]

				M. NAKAMURA, J. WADA, H. SUZUKI, M. TANAKA, M. KATANO, and T. MORISAKI Long-term Outcome of Immunotherapy for Patients with Refractory Pancreatic Cancer Anticancer Res, March 1, 2009; 29(3): 831 - 836. [Abstract] [Full Text] [PDF]

				C. KAMEDA, H. TANAKA, A. YAMASAKI, M. NAKAMURA, K. KOGA, N. SATO, M. KUBO, S. KUROKI, M. TANAKA, and M. KATANO The Hedgehog Pathway Is a Possible Therapeutic Target for Patients with Estrogen Receptor-negative Breast Cancer Anticancer Res, March 1, 2009; 29(3): 871 - 879. [Abstract] [Full Text] [PDF]

				F. Jiang, Q. Qiu, A. Khanna, N. W. Todd, J. Deepak, L. Xing, H. Wang, Z. Liu, Y. Su, S. A. Stass, et al. Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer Mol. Cancer Res., March 1, 2009; 7(3): 330 - 338. [Abstract] [Full Text] [PDF]

				K. J. Lavine and D. M. Ornitz Shared Circuitry: Developmental Signaling Cascades Regulate Both Embryonic and Adult Coronary Vasculature Circ. Res., January 30, 2009; 104(2): 159 - 169. [Abstract] [Full Text] [PDF]

				O. Nolan-Stevaux, J. Lau, M. L. Truitt, G. C. Chu, M. Hebrok, M. E. Fernandez-Zapico, and D. Hanahan GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation Genes & Dev., January 1, 2009; 23(1): 24 - 36. [Abstract] [Full Text] [PDF]

				X. Liao, M. K.Y. Siu, C. W.H. Au, E. S.Y. Wong, H. Y. Chan, P. P.C. Ip, H. Y.S. Ngan, and A. N.Y. Cheung Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation Carcinogenesis, January 1, 2009; 30(1): 131 - 140. [Abstract] [Full Text] [PDF]

				S. Bisht, G. Feldmann, J.-B. M. Koorstra, M. Mullendore, H. Alvarez, C. Karikari, M. A. Rudek, C. K. Lee, A. Maitra, and A. Maitra In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities Mol. Cancer Ther., December 1, 2008; 7(12): 3878 - 3888. [Abstract] [Full Text] [PDF]

				M Mimeault and S K Batra Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer Gut, October 1, 2008; 57(10): 1456 - 1468. [Abstract] [Full Text] [PDF]

				G Feldmann, N Habbe, S Dhara, S Bisht, H Alvarez, V Fendrich, R Beaty, M Mullendore, C Karikari, N Bardeesy, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer Gut, October 1, 2008; 57(10): 1420 - 1430. [Abstract] [Full Text] [PDF]

				P. J King, L. Guasti, and E. Laufer Hedgehog signalling in endocrine development and disease J. Endocrinol., September 1, 2008; 198(3): 439 - 450. [Abstract] [Full Text] [PDF]

				S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., September 1, 2008; 87(1): 97 - 130. [Abstract] [Full Text] [PDF]

				G. Feldmann, V. Fendrich, K. McGovern, D. Bedja, S. Bisht, H. Alvarez, J.-B. M. Koorstra, N. Habbe, C. Karikari, M. Mullendore, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2725 - 2735. [Abstract] [Full Text] [PDF]

				B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar Targeting Cancer Stem Cells with Phytochemicals Mol. Interv., August 1, 2008; 8(4): 174 - 184. [Abstract] [Full Text] [PDF]

				G.-M. Zou and A. Maitra Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration Mol. Cancer Ther., July 1, 2008; 7(7): 2012 - 2021. [Abstract] [Full Text] [PDF]

				R. J. Lipinski, P. R. Hutson, P. W. Hannam, R. J. Nydza, I. M. Washington, R. W. Moore, G. G. Girdaukas, R. E. Peterson, and W. Bushman Dose- and Route-Dependent Teratogenicity, Toxicity, and Pharmacokinetic Profiles of the Hedgehog Signaling Antagonist Cyclopamine in the Mouse Toxicol. Sci., July 1, 2008; 104(1): 189 - 197. [Abstract] [Full Text] [PDF]

				P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF]

				Y. A. Yoo, M. H. Kang, J. S. Kim, and S. C. Oh Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-{beta}-mediated activation of the ALK5-Smad 3 pathway Carcinogenesis, March 1, 2008; 29(3): 480 - 490. [Abstract] [Full Text] [PDF]

				G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF]

				V. Fendrich, J. Waldmann, F. Esni, A. Ramaswamy, M. Mullendore, M. Buchholz, A. Maitra, and G. Feldmann Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum Endocr. Relat. Cancer, September 1, 2007; 14(3): 865 - 874. [Abstract] [Full Text] [PDF]

				Z. Ji, F. C. Mei, J. Xie, and X. Cheng Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells J. Biol. Chem., May 11, 2007; 282(19): 14048 - 14055. [Abstract] [Full Text] [PDF]